Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 12, 2026
Gyre Therapeutics, Inc. (GYRE)
A forensic read on Gyre Therapeutics, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
15.0
Distress distance
Watch
Earnings quality
6
Forensic signals
-33.5
P / E (ttm)
9.3%
ROE
$740M
Market cap
0.00%
Dividend yield
10.2%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Gyre Therapeutics, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 15.0, placing it in the Safe zone. 6 forensic signals were flagged in its latest SEC filings, led by receivables vs revenue.
What the filings flag
79d DSO
FY2024→FY2025
Receivables vs revenue.Days sales outstanding moved from 60 to 79 days FY2024→FY2025 (receivables +59% vs revenue +10%). Receivables are outrunning sales — a flag for aggressive revenue recognition or slipping collections. Deferred revenue was roughly flat (-77%) over the same period, which doesn't corroborate a benign upfront-billing explanation for the receivables build. Measured against the same quarter twelve months earlier — like-for-like on the calendar, so an ordinary seasonal build cannot produce it — receivables took longer to collect in 3 consecutive quarters (Dec 2025 +12, Mar 2026 +9, Jun 2026 +11 days). In the latest of them the receivable balance grew +13% against sales -2%, so more of a quarter's billings were still outstanding at the period end than a year earlier — money the company has recognized and not yet been paid.
499d
FY2023→FY2024
Inventory days.Days inventory outstanding moved from 410 to 499 FY2023→FY2024 (against cost of goods sold; inventory +48% vs -16% in cost of sales). Inventory is outrunning what's being sold — a flag for softening demand or obsolescence risk ahead.
+10.9%/yr
FY2022–FY2025
Share-count dilution.Diluted share count changed +36% over the last 3 years to FY2025 (+10.9%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~10.9% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~27%.
791% of FCF
FY2022
Shareholder returns.Returned $45M to shareholders (buybacks + dividends) in FY2022 — 791% of free cash flow. More than free cash flow generated — and beyond operating cash too, so the extra is coming from debt or cash reserves, which isn't sustainable indefinitely.
Key fundamentals
Latest Revenue$116.6M
Revenue Growth YoY+10.2%
Revenue CAGR (3yr)+4.5%
Net Margin8.5%
Free Cash Flow-$180,000.00
Return on Equity9.3%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Gyre Therapeutics, Inc.'s actual 10-K/10-Q/8-K filings?
Data from SEC EDGAR public filings · metrics as of Aug 12, 2026. Forensic signals flag probability, not certainty.
+19.4%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +19.4% relative to their own average in FY2025 — scaled by NOA itself, not total assets (see the Forensic Screens card's differently-scaled Sloan Accrual Ratio for that read). Accruals are building faster than is comfortable — part of profit is sitting in the balance sheet rather than turning to cash. The build is led by receivables up +59% against revenue +10%. The cash-flow cross-check agrees: reported earnings ran ahead of operating cash by 9% of net operating assets.
7.1%
FY2025
Return on invested capital.Return on invested capital is 7.1% in the latest fiscal year and slipping from 13% — slightly below its ~10% cost of capital — reinvestment is roughly a wash.
Gyre Therapeutics, Inc. (GYRE) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy